| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-01-16 | fruquintinib | non-small cell lung cancer (NSCLC) | 2 | Hutchison China MediTech Limited "ChiMed" (China) | Cancer - Oncology |
| 2017-01-13 | cenicriviroc (CVC) | liver fibrosis in adult subjects with NASH | 3 | Tobira Therapeutics (USA - CA), now Allergan (Ireland) | Hepatic diseases - Liver diseases |
| 2017-01-13 | Spinraza™ -nusinersen - ISIS-SMNRx (antisense oligonucleotide targeted to the SMN2 gene) | spinal muscular atrophy | 3 | Ionis Pharmaceuticals (USA - CA) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2017-01-12 | PLX-PAD cells | intermittent claudication | 2 | Pluristem Therapeutics (Israel) | Cardiovascular diseases |
| 2017-01-12 | Lutathera® ([177]Lutetium-DOTA[0]-Tyr[3]-Octreotate) | inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors | 3 | Advanced Accelerator Applications (France) | Cancer - Oncology |
| 2017-01-12 | bimagrumab (BYM338) | obese patients with type 2 diabetes | 2 | Novartis (Switzerland) | Metabolic diseases |
| 2017-01-12 | picornavirus infections | preclinical | Haplogen (Austria) | Infectious diseases | |
| 2017-01-11 | SFX-01 | aneurysmal subarachnoid haemorrhage | 2 | Evgen Pharma (UK) | Cerebrovascular diseases |
| 2017-01-11 | TG-1101 (ublituximab) | multiple sclerosis | 2 | TG Therapeutics (USA - NY) | Autoimmune diseases - Neurodegenerative diseases |
| 2017-01-11 | ALX-0171 | respiratory syncytial virus lower respiratory tract infection | 2 | Ablynx (Belgium) | Infectious diseases - Respiratory diseases |
| 2017-01-10 | CPI-444 | solid tumors | 1-1b | Corvus Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-01-10 | Parsabiv™ (etelcalcetide - AMG 416) | secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis | 3 | Amgen (USA - CA) | Kidney diseases - Metabolic diseases - Renal diseases |
| 2017-01-10 | RHB-105 (amoxicillin, rifabutin and omeprazole) | Helictobacter pylori infection | 1 | RedHill Biopharma (Israel) | Infectious diseases |
| 2017-01-10 | CHS-1420 (biosimilar version of Humira® (adalimumab)) | plaque psoriasis | 3 | Coherus Biosciences (USA - CA) | Autoimmune diseases - Dermatological diseases |
| 2017-01-10 | PLX-PAD cells | critical limb ischemia | 3 | Pluristem Therapeutics (Israel) | Cardiovascular diseases |
| 2017-01-10 | AUT00206 | schizophrenia | 1a | Autifony Therapeutics (UK) | CNS diseases - Mental diseases |
| 2017-01-10 | AUT00206 | schizophrenia | 1b | Autifony Therapeutics (UK) | CNS diseases - Mental diseases |
| 2017-01-10 | Debio 1450 | Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci | 2 | Debiopharm (Switzerland) | Infectious diseases |
| 2017-01-09 | voretigene neparvovec - SPK-RPE65 | inherited retinal disease (IRD) caused by biallelic RPE65 mutations. | 1 | Spark Therapeutics (USA - PA) | Rare diseases - Genetic diseases - Ophtalmological diseases |
| 2017-01-09 | RG6016 | small cell lung cancer | 1 | Roche (Switzerland) | Cancer - Oncology |
